The mystery started last June. That's when Novartis AG disclosed top-line results from the tests that pitted its VEGF-A ligand inhibitor, brolucizumab (RTH-258), in neovascular age-related macular degeneration (AMD) against Regeneron Pharmaceuticals Inc.'s flagship product, Eylea (aflibercept).